The KCTD12 Knockout HT29 Polyclonal Cells constitute a genetically engineered loss-of-function model featuring CRISPR/Cas9-mediated disruption of the KCTD12 gene within the HT29 human colorectal adenocarcinoma cell line. This polyclonal knockout population is derived after targeted gene editing, providing a heterogeneous pool of cells with diverse mutations at the KCTD12 locus, suitable for analyzing the collective consequences of gene inactivation. The product serves as a versatile tool for dissecting KCTD12-dependent processes, including ubiquitin-mediated proteolysis, ion channel regulation, and tumor suppression, in a well-established epithelial cancer background.
The HT29 cell line is isolated from a primary colorectal adenocarcinoma and is widely utilized in cancer research due to its epithelial morphology, ability to form tight monolayers, and relevance to intestinal epithelial biology. It is a standard model for studying drug absorption, toxicity, and the molecular mechanisms underlying colorectal cancer progression. The cells exhibit characteristic features of the colorectal adenocarcinoma-derived epithelium, making them particularly suited for investigations into oncogenic signaling, barrier function, and pharmacological responses.
KCTD12 functions as a substrate-specific adaptor for the Cullin3-RING E3 ubiquitin ligase complex (CUL3/RBX1), mediating the ubiquitination and subsequent proteasomal degradation of target proteins. It is an integral regulator of GABA-B receptor (GABBR1/GABBR2) surface expression and modulates neuronal excitability through direct interaction with KCNQ2 and KCNQ3 potassium channels. KCTD12 activity is influenced by upstream regulators such as Wnt/??-catenin signaling (TCF/LEF) and promoter methylation, while its downstream effects converge on protein substrates destined for CUL3-dependent degradation. The protein interacts with KCTD8, suggesting functional cooperativity within the KCTD family.
In the colorectal adenocarcinoma context, KCTD12 is proposed to act as a tumor suppressor by targeting oncogenic substrates for proteasomal turnover. Its loss may disrupt ubiquitination dynamics, alter Wnt pathway signaling, and modify GABA-B receptor and potassium channel-associated cellular phenotypes. The HT29 knockout model thus enables the exploration of KCTD12-dependent tumor suppressive mechanisms, as well as the interplay between ubiquitin-proteasome system and colorectal cancer pathways, within an epithelial background that retains relevant oncogenic drivers.
Researchers can employ these polyclonal knockout cells in a wide array of experimental paradigms, including Western blotting, RT-qPCR, and RNA-seq to validate gene disruption and downstream transcriptional changes; co-immunoprecipitation with CUL3 and ubiquitination assays to probe substrate modification; immunofluorescence for GABA-B receptor trafficking; and patch-clamp electrophysiology to assess potassium channel function. Functional studies such as cell proliferation, apoptosis, drug sensitivity, and migration/invasion assays further support applications in tumor biology and drug response screening. These cells provide a robust platform for identifying novel CUL3 substrates and dissecting KCTD12 signaling networks. For additional details and support, please contact Ascent Research.
